| ［1］ Ghzili H, Grumolato L, Thou?nnon E, et al. Role of PACAP in the physiology and pathology of the sympathoadrenal system. Front Neuroendocrinol, 2008, 29(1):128~141
［2］ Winzell M S, Ahrén B. Role of VIP and PACAP in islet function. Peptides, 2007, 28(9):1805~1813
［3］ Pan C Q, Li F, Tom I, et al. Engineering novel VPAC2-selective agonists with improved stability and glucose-lowering activity in vivo. J Pharmacol Exp Ther, 2007, 320(2):900~906
［4］ Yung S L, Cruz F D, Hamren S, et al. Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclaseactivating peptide. J Biol Chem, 2003, 278(12):10273~10281
［5］ Tsutsumi M, Claus T H, Liang Y, et al. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal, a potential therapy for type 2 diabetes. Diabetes, 2002, 51(5):1453~1460
［6］ Yu R J, Xie Q L, Dai Y, et al. Intein-mediated rapid purification and characterization of a novel recombinant agonist for VPAC2. Peptides, 2006, 27 (6):1359~1366
［7］ Wilson R J, Cummings K J. Pituitary adenylate cyclase-activating polypeptide is vital for neonatal survival and the neuronal control of breathing. Respir Physiol Neurobiol, 2008, 164(1-2): 168~178
［8］ Yu R J, TAM N L, Gao Y, et al. A novel recombinant, VPAC2-selective agonist enhancing insulin release and glucose disposal. Acta Pharmacol Sin, 2007, 28(4):526~533
［9］ Moreno D, Gourlet P, De Neef P, et al. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC2 receptor. Peptides, 2000, 21(10):1543~1549
［10］ Juarranz M G, Rampelbergh J V, Gourlet P, et al. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC2-selective ligands. Mol Pharmacol, 1999, 56(6):1280~1287 |
